# ACR-2316

Source: https://onco.cc/drugs/acr-2316/  
OnCo record `acr-2316` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ACR-2316 is an experimental small molecule from Acrivon Therapeutics, in phase 1 trials for lung cancer, endometrial cancer and cervical cancer and other cancers.

## Summary

ACR-2316 is a small molecule (oral) from Acrivon Therapeutics. A selective dual inhibitor of WEE1 and PKMYT1 that Acrivon designed with its AP3 phosphoproteomics platform. Its furthest stage is phase 1, for lung cancer, endometrial cancer, cervical cancer and oesophago-gastric junction cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 study moved into randomised dose expansion (Q2 2026 results release, 12 August 2026). Registry phase PHASE1/PHASE2, RECRUITING. Stage given as phase-1 because the study is phase 1/2 and is in dose expansion. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: ACR-2316
- Modality: Small molecule (oral)
- Mechanism: A selective dual inhibitor of WEE1 and PKMYT1 that Acrivon designed with its AP3 phosphoproteomics platform.

## Sources

- Acrivon Therapeutics: acrivon.com: https://acrivon.com/pipeline/
- Acrivon Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-ex99_1.htm
- Acrivon Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06667141
- ClinicalTrials.gov: trials of ACR-2316: https://clinicaltrials.gov/search?intr=ACR-2316

## Connected records

- targets: [WEE1](https://onco.cc/targets/wee1/)
- companies: [Acrivon Therapeutics](https://onco.cc/companies/acrivon-therapeutics/)
- trials: [Study of ACR-2316 in Specific Advanced Solid Tumors](https://onco.cc/trials/nct06667141/)

---
JSON: https://onco.cc/api/v1/entities/acr-2316.json